Skip to content

Application of PREVENA in Reducing Surgical Site Complications Following Reversal of Ileostomy or Colostomy

Application of PREVENA (Surgical Incision Protection System) in Reducing Surgical Site Complications Following Reversal of Ileostomy or Colostomy: A Randomized Controlled Trial (PRIC Trial)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04974931
Acronym
PRIC
Enrollment
50
Registered
2021-07-23
Start date
2021-11-01
Completion date
2022-05-01
Last updated
2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stoma Site Infection, Ileostomy - Stoma, Colostomy Stoma

Brief summary

Surgical site infections (SSI) remain one of the most common complications associated with reversal of ileostomy and colostomy. In addition to having detrimental impacts on the patient's post-operative course, they also pose significant financial ramifications. There have been comparative studies in the use of negative pressure wound therapy in reducing surgical site infections. PREVENA Incision Management System is a type of disposable, customizable and powered negative pressure system designed to help manage and protect surgical incisions and their surrounding environment. It is now commonly used as a surgical wound dressings in the setting of vascular surgeries, post-cesarean infections and colorectal resections. Our study is designed as a randomised controlled trial to examine if PREVERA therapy as a NPWT is more superior than conventional dressings in reducing the rate of surgical site infections.

Detailed description

Background: Surgical site infections (SSI) remain one of the most common complications associated with reversal of ileostomy. In addition to having detrimental impacts on the patient's post-operative course, they also pose significant financial ramifications. The use of Negative Pressure Wound Therapy (NPWT) is one strategy that has been extensively studied in reducing the rate of surgical site infections. PREVENA Therapy is a form of Incisional Negative Pressure Wound Therapy (INPWT) that has been widely used in the management of closed surgical incisions. They are delivered as prophylactic measures in preventing surgical complications such as surgical site infections. Trial Design: This study is designed as a randomized, controlled, open-label, multi-center superiority trial with 2 parallel groups and primary endpoint of surgical site infection at day 7 (after 7-day use of PREVENA) and day 30. Study Setting The trial will be conducted at two different hospitals located in Dublin, Ireland: St James Hospital - Ireland's largest acute academic teaching hospital (Academic Partner - Trinity College Dublin); Tallaght University Hospital - (Academic Partner - Trinity College Dublin)

Interventions

Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the

Sponsors

St. James's Hospital, Ireland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized, controlled, open-label, multi-center superiority trial with 2 parallel groups and primary endpoint of surgical site infection at day 7 (after 7-day use of PREVENA) and day 30.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged over 18 years old * Patients undergoing elective reversal of ileostomy/colostomy * Patients who agree to consent to inclusion and follow-up protocol

Exclusion criteria

* Patients who do not fulfil study protocol * Dressings being removed outside defined time periods * Patients who do not attend for regular outpatient follow up appointments

Design outcomes

Primary

MeasureTime frameDescription
To measure surgical site infection incidence on outpatient follow up post reversal ileostomy/colostomyFour to Six weeksThe investigators will be assessing and measuring the incidence of surgical site incidence on follow up appointments

Secondary

MeasureTime frameDescription
To measure surgical site infection incidence on day 5 post reversal ileostomy/colostomy (or earlier, if deemed fit for discharge prior to day 5)Five days post reversal ileostomy/colostomyThe investigators will be assessing and measuring the incidence of surgical site incidence on day 5 post reversal ileostomy/colostomy
To measure the time to wound healingOne to Four weeksThe investigators will be assessing and measuring the time to wound healing based on the duration and last appointment date of home visits by public healthcare nurses involving wound care management

Countries

Ireland

Contacts

Primary ContactErnest Low
lowe@tcd.ie+353 (01) 410 3000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026